This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Signed cohort-specific Informed Consent Form
Age >= 18 years at time of signing Informed Consent Form
A validated test approved by local health authorities for detection of the specified biomarkers/mutations.
A validated test performed at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA) -certified or equivalently accredited diagnostic laboratory using a validated test for detection of the specified biomarkers.
Current participation or enrollment in another interventional clinical trial. Participants who are participating in the follow-up period of an interventional clinical trial are eligible for the study.
Any systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Pregnant or breastfeeding, or intending to become pregnant during the study
10
Treatment groupsSee each treatment group below.